Neural network analysis as a novel skin outcome in a trial of belumosudil in patients with systemic sclerosis

By sjmartinez • April 12, 2025

Gunes I, Bernstein EJ, Cowper SE, Panse G, Pradhan N, Camacho LD, Page N, Bundschuh E, Williams A, Carns M, Aren K, Fantus S, Volkmann ER, Bukiri H, Correia C, Kolachalama VB, Wilson FP, Mawe S, Mahoney JM, Hinchcliff M. Neural network analysis as a novel skin outcome in a trial of belumosudil in patients with systemic sclerosis. Arthritis Res Ther. 2025 Apr 11;27(1):85. doi: 10.1186/s13075-025-03508-9. PMID: 40217251; PMCID: PMC11987334.

Tags: AlexNet, Artificial intelligence, Belumosudil, Deep Neural Network, Dermal fibrosis, Modified Rodnan skin score, outcome measure, Outcomes, Publications, Rheumatology, Scleroderma, Skin fibrosis, systemic sclerosis

The role of declining therapy volumes in skilled nursing facility outcomes: a mediation analysis

Prusynski RA, Humbert A, Amaravadi H, Burke RE, Saliba D, Leland NE, Freburger J, Mroz TM. The role of declining therapy volumes in skilled nursing[...]

Bloodstream Infections Among Veterans With Cardiac Implantable Electronic Devices: Source Identification and Intervention Strategies

Basnet D, Golenbock S, Strymish JM, Mull HJ, Lamkin RP, Shin M, Harvey K, Karchmer AW, Branch-Elliman W. Bloodstream Infections Among Veterans With Cardiac Implantable[...]

FRONTIER-3: a randomised phase 2a study to investigate tozorakimab, an anti-interleukin-33 monoclonal antibody, in early-onset asthma

Corren J, Reid F, Moate R, Jimenez E, Sadiq MW, Williams A, Rytelewski M, Cameron-Christie S, Muthas D, Georgi B, Brooks D, Lindqvist E, Kell[...]